For the past few years, the biosimilars industry has been growing stupendously across the globe due to increasing healthcare costs and rising aging population. It is expected to evolve, to a great extent, from its current status. As per the estimations of our latest report, the global biosimilars market will expand at a CAGR of around 52% during 2010-2015. As the governments and private players around the world are stepping into the market, it is exhibiting bright prospects and immense opportunities to cash in on.
According to “G-CSF Biosimilars Market Forecast to 2015”, the overall market is presently dominated by first-generation biosimilars, and it is likely that their second-generation will grow phenomenally in the future. The Granulocyte colony-stimulating factor (G-CSF) biologics/biosimilars stimulate the production of neutrophils. In 2010, the G-CSF biosimilars had a 33% share in the global biosimilars market. It is expected that the patent expiries of Neupogen (filgrastim) in 2013 and Neulasta (pegfilgrastim) in 2015 will make the way for the entry of G-CSF biosimilars into the market. It is anticipated that the G-CSF biosimilars market will touch the US$ 350 Million-mark by 2015.
Our report analyzes the market for the global G-CSF biosimilars and looks into the recent activities in the segment. On studying the market trends and drivers, we found that rising business alliances are aiding the biosimilars development, and governments around the world are realizing the potential in biosimilars. The competitive landscape talks about the activities of companies like Sandoz, Hospira and Hexal, and their key G-CSF products. Overall, the extensive research presents an objective outlook of the global G-CSF biosimilars market to clients.
